News 02.04.2019 The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy to maintain initial vision gains in all patients on a true fixed 12-week dosing interval Abicipar BLA submission to...
News 29.03.2019 Zurich-Schlieren, Switzerland, March 29, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin® directed drug delivery (DDC) platforms at the Annual Meeting 2019...
News 25.03.2019 SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to...
Internal events
Event date: 09.04.2019
If you like to get a 30 minutes IP coaching from Ute-Christine Konopka from thinksafe, you have to think about the challenges you have with IP in your own business. If you have decided to go the „non-IP“ path, even then you have to be aware of some traps you can...
Internal events
Event date: 16.04.2019
Zeit: 17:00 – 17:45, anschliessend Fragen & Antworten
Ort: Auditorium Wagistrasse 25
Themen:
NDA: Einseitig/Zweiseitig, Umfang, Überbindungspflicht, Vertragsdauer, Konventionalstrafe, Gerichtsstand/anwendbares Recht.
Supply Agreement: Produkteänderungen, Preisklauseln, Preisänderungen, Lieferpflicht, Gewährleistung, Haftung
Vertriebsverträge: Exklusivität, Abnahmepflichten/Minimalvolumen, Marketingaktivität, After-Sales, IP
Master Service Agreement: konkrete Resultate, persönliche Ausführung, IP in Bezug auf Resultate, Haftung
Referent: Dr. Michael Tschudin
Michael Tschudin...